AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33813550 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine IV administered without a loading dose at age-specific dose regimens 0.2-1.4 µg/kg/hr (< 6 yr) and 0.2-1.0 µg/kg/hr (≥ 6 yr)
Number of subjects: 61
Study 33813550 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine IV administered
Number of subjects: 61
Study 33813580 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injection
Number of subjects: 252
Study 33813580 — intervention group
Group type: COMPARATOR
Intervention: Intravenous injection
Number of subjects: 252
Study 33813580 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of subcutaneous injection risk
Number of subjects: 252
Study 33813631 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative management
Number of subjects: 338
Study 33813631 — intervention group
Group type: COMPARATOR
Intervention: Non-operative management
Number of subjects: 338
Study 33813631 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 338
Study 33813631 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative management
Number of subjects: 338
Study 33813631 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative mortality
Number of subjects: 338
Study 33813637 — intervention group
Group type: EXPERIMENTAL
Intervention: Antifungal therapy
Number of subjects: 90
Study 33813637 — intervention group
Group type: EXPERIMENTAL
Intervention: Candida positive NHL
Number of subjects: 90
Study 33813637 — intervention group
Group type: EXPERIMENTAL
Intervention: Candida positive HL
Number of subjects: 90
Study 33813637 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (C)
Number of subjects: 90
Study 33813673 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 772
Study 33813727 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 3.75 mg DAPT
Number of subjects: 203
Study 33813736 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin
Number of subjects: 25
Study 33813771 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with recent onset of excessive daytime sleepiness (EDS), hypersomnia, or a suspected central disorder of hypersomnolence (CDH)
Number of subjects: 500
Study 33813771 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 500
Study 33813771 — intervention group
Group type: COMPARATOR
Intervention: Patients with EDS due to severe sleep-disordered breathing, improving after therapy
Number of subjects: 500
Study 33813842 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored treatment of nonphysiologic hemodynamic adjustments to pregnancy
Number of subjects: 0
Study 33813864 — intervention group
Group type: EXPERIMENTAL
Intervention: More than 3 retrieval attempts
Number of subjects: 593
Study 33813864 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Alberta Stroke Program Early CT Score of 8 to 9
Number of subjects: 593
Study 33813864 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Alberta Stroke Program Early CT Score of 10
Number of subjects: 593
Study 33813864 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrieval passes (median number 2, interquartile range 1–3)
Number of subjects: 593
Study 33814177 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative swallowing evaluation
Number of subjects: 182
Study 33814177 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for aspiration
Number of subjects: 182
Study 33814177 — intervention group
Group type: COMPARATOR
Intervention: Comparison of aspirators vs nonaspirators
Number of subjects: 182
Study 33814177 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspiration outcomes
Number of subjects: 182
Study 33814284 — intervention group
Group type: EXPERIMENTAL
Intervention: PGD patients
Number of subjects: 99
Study 33814284 — intervention group
Group type: EXPERIMENTAL
Intervention: PGD patients who developed CLAD
Number of subjects: 99
Study 33814284 — intervention group
Group type: COMPARATOR
Intervention: Non-PGD patients
Number of subjects: 99
Study 33815252 — intervention group
Group type: EXPERIMENTAL
Intervention: Home group (H) - 7 outpatients
Number of subjects: 28
Study 33815252 — intervention group
Group type: COMPARATOR
Intervention: Hospital group (URI) - 21 outpatients
Number of subjects: 28
Study 33815252 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received 10 days of exergaming over 2 weeks, each session lasting a maximum of 1 hour.
Number of subjects: 28
Study 33816283 — intervention group
Group type: EXPERIMENTAL
Intervention: Cs-131 implant after surgical resection
Number of subjects: 12
Study 33816524 — intervention group
Group type: EXPERIMENTAL
Intervention: PT-Cy combined with tacrolimus and low-dose ATG
Number of subjects: 23
Study 33817379 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac 25 mg/mL applied after laser microporation of cNF, reapplied twice daily for 3 days.
Number of subjects: 6
Study 33817379 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline applied after laser microporation of cNF, reapplied twice daily for 3 days.
Number of subjects: 6
Study 33817538 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative insufficient endogenous analgesia
Number of subjects: 146
Study 33817538 — intervention group
Group type: COMPARATOR
Intervention: Preoperative sufficient endogenous analgesia
Number of subjects: 146
Study 33817538 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patient population
Number of subjects: 146
Study 33817538 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative sensory testing
Number of subjects: 146
Study 33817543 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous carriers of the major risk alleles for low iron status
Number of subjects: 251
Study 33817543 — intervention group
Group type: COMPARATOR
Intervention: Non-carriers of the major risk alleles for low iron status
Number of subjects: 251
Study 33817650 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoablation
Number of subjects: 66
Study 33817648 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body diffusion-weighted MRI (WB-DW MRI) after one treatment cycle of immunochemotherapy.
Number of subjects: 45
Study 33817648 — intervention group
Group type: COMPARATOR
Intervention: Interim assessment using Deauville criteria.
Number of subjects: 45
Study 33817648 — intervention group
Group type: COMPARATOR
Intervention: End-of-treatment assessment using Deauville criteria.
Number of subjects: 45
Study 33817686 — intervention group
Group type: EXPERIMENTAL
Intervention: MORPH intervention (mobile health behavior intervention)
Number of subjects: 0
Study 33817686 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33817763 — intervention group
Group type: EXPERIMENTAL
Intervention: Working from home
Number of subjects: 69
Study 33817763 — intervention group
Group type: EXPERIMENTAL
Intervention: Each working hour at the computer
Number of subjects: 69
Study 33817763 — intervention group
Group type: EXPERIMENTAL
Intervention: Each work break taken
Number of subjects: 69
Study 33817763 — intervention group
Group type: EXPERIMENTAL
Intervention: Workstation ergonomics at home
Number of subjects: 69
Study 33817960 — intervention group
Group type: EXPERIMENTAL
Intervention: High DAPT score (DS ≧2)
Number of subjects: 8383
Study 33817960 — intervention group
Group type: COMPARATOR
Intervention: Low DAPT score (DS <2)
Number of subjects: 8383
Study 33817960 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended DAPT group (high DS)
Number of subjects: 8383
Study 33817960 — intervention group
Group type: COMPARATOR
Intervention: Conventional DAPT group (low DS)
Number of subjects: 8383
Study 33818006 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization of PAD
Number of subjects: 30
Study 33818022 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant letrozole (2.5 mg/daily) for 5 years
Number of subjects: 440
Study 33818037 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic response to OGTT
Number of subjects: 69
Study 33818226 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulants, alone or in combination with antiplatelet (AP)
Number of subjects: 2396
Study 33818698 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular (LV) and left atrial (LA) myocardial deformation parameters (including global longitudinal strain (GLS), radial strain, circumferential strain, LA reservoir strain (LAε))
Number of subjects: 250
Study 33819069 — intervention group
Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet
Number of subjects: 0
Study 33819069 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33819614 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid (ICS) treatment
Number of subjects: 42
Study 33819776 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiMEDs intervention
Number of subjects: 148
Study 33820423 — intervention group
Group type: EXPERIMENTAL
Intervention: WATCHMAN FLX LAA closure device
Number of subjects: 400
Study 33820434 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylation quantitative trait locus analysis
Number of subjects: 0
Study 33820562 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning model based on intraoperative monitoring data
Number of subjects: 699
Study 33820562 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning model based on intraoperative intervention data
Number of subjects: 699
Study 33820562 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning model based on combined preoperative, intraoperative intervention, and monitoring data
Number of subjects: 699
Study 33820562 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression model based on intraoperative monitoring data
Number of subjects: 699
Study 33820562 — intervention group
Group type: EXPERIMENTAL
Intervention: Random forest model based on intraoperative monitoring data
Number of subjects: 699
Study 33820779 — intervention group
Group type: EXPERIMENTAL
Intervention: Sapanisertib plus exemestane (3 to 5 mg daily in phase IB, 25 mg daily)
Number of subjects: 118
Study 33820779 — intervention group
Group type: EXPERIMENTAL
Intervention: Sapanisertib plus fulvestrant (4 mg daily, 500 mg monthly)
Number of subjects: 118
Study 33820779 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 118
Study 33820780 — intervention group
Group type: EXPERIMENTAL
Intervention: ABBV-085 monotherapy at 3.6 mg/kg
Number of subjects: 85
Study 33820780 — intervention group
Group type: EXPERIMENTAL
Intervention: ABBV-085 plus gemcitabine
Number of subjects: 85
Study 33820780 — intervention group
Group type: EXPERIMENTAL
Intervention: ABBV-085 at 3.6 mg/kg every 14 days
Number of subjects: 85
Study 33820783 — intervention group
Group type: EXPERIMENTAL
Intervention: Pepinemab (10 mg/kg) with Avelumab (10 mg/kg), every 2 weeks
Number of subjects: 62
Study 33820851 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary antibiotic prophylaxis
Number of subjects: 53
Study 33820851 — intervention group
Group type: EXPERIMENTAL
Intervention: Definite rheumatic heart disease
Number of subjects: 53
Study 33820851 — intervention group
Group type: EXPERIMENTAL
Intervention: Borderline rheumatic heart disease
Number of subjects: 53
Study 33820851 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall disease progression
Number of subjects: 53
Study 33820958 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified in vivo assay of hepatic propionate oxidative capacity
Number of subjects: 0
Study 33820958 — intervention group
Group type: EXPERIMENTAL
Intervention: Propionate oxidative capacity measurement
Number of subjects: 0
Study 33822526 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR-T cell therapy
Number of subjects: 0
Study 33822795 — intervention group
Group type: EXPERIMENTAL
Intervention: Rural children with anemia
Number of subjects: 1281
Study 33822795 — intervention group
Group type: EXPERIMENTAL
Intervention: Urban children with anemia
Number of subjects: 1281
Study 33822795 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined sample
Number of subjects: 1281
Study 33822795 — intervention group
Group type: COMPARATOR
Intervention: Households with more adults
Number of subjects: 1281
Study 33822828 — intervention group
Group type: EXPERIMENTAL
Intervention: Pf-iRBC stimulation in Malian adults
Number of subjects: 3
Study 33822828 — intervention group
Group type: EXPERIMENTAL
Intervention: Pf-iRBC stimulation in Malian children
Number of subjects: 3
Study 33822828 — intervention group
Group type: EXPERIMENTAL
Intervention: Macrophages re-exposed to Pf-iRBCs
Number of subjects: 3
Study 33822828 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocytes of Malian adults
Number of subjects: 3
Study 33822961 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33823018 — intervention group
Group type: EXPERIMENTAL
Intervention: PFS1 (complete mutism)
Number of subjects: 178
Study 33823018 — intervention group
Group type: EXPERIMENTAL
Intervention: PFS2 (diminished speech)
Number of subjects: 178
Study 33823018 — intervention group
Group type: EXPERIMENTAL
Intervention: PFS1
Number of subjects: 178
Study 33823018 — intervention group
Group type: EXPERIMENTAL
Intervention: PFS2
Number of subjects: 178
Study 33823018 — intervention group
Group type: EXPERIMENTAL
Intervention: All children with PFS
Number of subjects: 178
Study 33823051 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine-specific medications
Number of subjects: 170
Study 33823051 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute medication use
Number of subjects: 170
Study 33823051 — intervention group
Group type: COMPARATOR
Intervention: No medication
Number of subjects: 170
Study 33823051 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine-specific medication use
Number of subjects: 170
Study 33823051 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age and higher educational attainment
Number of subjects: 170
Study 33823051 — intervention group
Group type: EXPERIMENTAL
Intervention: Naturalistic assessment factors
Number of subjects: 170
Study 33823783 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual risk reduction intervention in addition to hepatitis C treatment
Number of subjects: 17
Study 33823811 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS
Number of subjects: 100
Study 33823811 — intervention group
Group type: EXPERIMENTAL
Intervention: SedLine
Number of subjects: 100
Study 33823811 — intervention group
Group type: COMPARATOR
Intervention: Clinical assessments of anesthesia depth
Number of subjects: 100
Study 33823862 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 1057
Study 33823862 — intervention group
Group type: COMPARATOR
Intervention: Control (non-prone position)
Number of subjects: 1057
Study 33823929 — intervention group
Group type: EXPERIMENTAL
Intervention: High visceral adiposity
Number of subjects: 200
Study 33823929 — intervention group
Group type: EXPERIMENTAL
Intervention: Frozen tissue DDX11 expression
Number of subjects: 200
Study 33824079 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise (marathon running)
Number of subjects: 31
Study 33824433 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrabone (IB) infusion of umbilical cord blood transplantation (UCBT)
Number of subjects: 15
Study 33824442 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day decitabine (20 mg/m2) combined with fludarabine and 2 Gray TBI prior to allogeneic hematopoietic cell transplantation (allo HCT)
Number of subjects: 0
Study 33824442 — intervention group
Group type: COMPARATOR
Intervention: Standard non-myeloablative (NMA) conditioning regimen
Number of subjects: 0
Study 33824476 — intervention group
Group type: EXPERIMENTAL
Intervention: Tepotinib (500 mg daily)
Number of subjects: 66
Study 33825230 — intervention group
Group type: COMPARATOR
Intervention: Add-on cannabidiol (two doses)
Number of subjects: 1277
Study 33825230 — intervention group
Group type: COMPARATOR
Intervention: Add-on cinromide
Number of subjects: 1277
Study 33825230 — intervention group
Group type: COMPARATOR
Intervention: Add-on clobazam (three doses)
Number of subjects: 1277
Study 33825230 — intervention group
Group type: COMPARATOR
Intervention: Add-on felbamate
Number of subjects: 1277
Study 33825230 — intervention group
Group type: COMPARATOR
Intervention: Add-on lamotrigine
Number of subjects: 1277
Study 33825230 — intervention group
Group type: COMPARATOR
Intervention: Add-on rufinamide
Number of subjects: 1277
Study 33825230 — intervention group
Group type: COMPARATOR
Intervention: Add-on topiramate
Number of subjects: 1277
Study 33825489 — intervention group
Group type: EXPERIMENTAL
Intervention: Etelcalcetide
Number of subjects: 0
Study 33825489 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33825692 — intervention group
Group type: EXPERIMENTAL
Intervention: FibriCheck app
Number of subjects: 92
Study 33825765 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 0
Study 33825765 — intervention group
Group type: EXPERIMENTAL
Intervention: AV-101
Number of subjects: 0
Study 33825765 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanicemine
Number of subjects: 0
Study 33825916 — intervention group
Group type: EXPERIMENTAL
Intervention: Motion-compensated PET/CT
Number of subjects: 37
Study 33825916 — intervention group
Group type: COMPARATOR
Intervention: 3D PET/CT
Number of subjects: 37
Study 33825965 — intervention group
Group type: EXPERIMENTAL
Intervention: P2X3-Receptor Antagonist Gefapixant
Number of subjects: 253
Study 33825965 — intervention group
Group type: COMPARATOR
Intervention: Prior medications (inhaled/oral steroids, antihistamines, antacids)
Number of subjects: 253
Study 33826106 — intervention group
Group type: EXPERIMENTAL
Intervention: Ravulizumab (weight-based doses administered on days 1, 5, 10, and 15)
Number of subjects: 22
Study 33826106 — intervention group
Group type: EXPERIMENTAL
Intervention: Ravulizumab (modified dosing regimen)
Number of subjects: 22
Study 33826112 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab treatment (a complement C5 inhibitor)
Number of subjects: 51
Study 33826209 — intervention group
Group type: EXPERIMENTAL
Intervention: Omecamtiv mecarbil, dosage and duration not available
Number of subjects: 0
Study 33826209 — intervention group
Group type: COMPARATOR
Intervention: Control group, treatment not specified
Number of subjects: 0
Study 33826362 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (replacing vincristine in the OEPA/COPDac regimen); two cycles of AEPA and four cycles of CAPDac; residual node radiotherapy (25.5 Gy) for non-CR sites after chemotherapy
Number of subjects: 77
Study 33826508 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33826695 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt consumption (per 25 g/d)
Number of subjects: 4365
Study 33826695 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat milk consumption (per 100 g/d)
Number of subjects: 4365
Study 33826695 — intervention group
Group type: EXPERIMENTAL
Intervention: Total nonfermented milk consumption (per 100 g/d)
Number of subjects: 4365
Study 33826695 — intervention group
Group type: EXPERIMENTAL
Intervention: Hard cheese consumption
Number of subjects: 4365
Study 33826695 — intervention group
Group type: EXPERIMENTAL
Intervention: Other dairy groups
Number of subjects: 4365
Study 33826697 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie diet (LCD) 900-1000 kcal/d for 28 days
Number of subjects: 37
Study 33826820 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutimlimab
Number of subjects: 24
Study 33826860 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Advance Care Planning Elements in the Electronic Health Record
Number of subjects: 0
Study 33827114 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib (20/36 mg/m2), Lenalidomide (25 mg), Dexamethasone (20 mg) for 8 cycles followed by transplant and 1 year of lenalidomide maintenance (10 mg)
Number of subjects: 46
Study 33827114 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib (20/36 mg/m2), Lenalidomide (25 mg), Dexamethasone (20 mg)
Number of subjects: 46
Study 33827116 — intervention group
Group type: EXPERIMENTAL
Intervention: KTE-X19 at 1 × 10^6 cells per kg
Number of subjects: 54
Study 33827116 — intervention group
Group type: EXPERIMENTAL
Intervention: KTE-X19 in all patients
Number of subjects: 54
Study 33827116 — intervention group
Group type: EXPERIMENTAL
Intervention: KTE-X19 with revised AE management at 1 × 10^6 cells per kg
Number of subjects: 54
Study 33827139 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV) combined with nivolumab (Nivo)
Number of subjects: 91
Study 33827446 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver Activity Scale (CAS)
Number of subjects: 524
Study 33827446 — intervention group
Group type: EXPERIMENTAL
Intervention: Zarit Burden Interview (ZBI)
Number of subjects: 524
Study 33827446 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of dementia diagnosis (caregivers)
Number of subjects: 524
Study 33827446 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of dementia diagnosis (patients)
Number of subjects: 524
Study 33827501 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced after-school programming with structured nutrition education and minimum physical activity requirements
Number of subjects: 76
Study 33827611 — intervention group
Group type: EXPERIMENTAL
Intervention: Overnight sleep registration for OSA diagnosis
Number of subjects: 49
Study 33827611 — intervention group
Group type: EXPERIMENTAL
Intervention: Berlin Questionnaire
Number of subjects: 49
Study 33827675 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose metabolism in the right middle temporal gyrus (RMTG)
Number of subjects: 149
Study 33827675 — intervention group
Group type: COMPARATOR
Intervention: Normal control (NC)
Number of subjects: 149
Study 33827675 — intervention group
Group type: EXPERIMENTAL
Intervention: RMTG metabolism
Number of subjects: 149
Study 33827827 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pharmacy activities during the interventional period
Number of subjects: 69
Study 33827861 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic retinopathy (DR) eyes
Number of subjects: 62
Study 33827861 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 62
Study 33827861 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic retinopathy (DR) eyes with proliferative DR
Number of subjects: 62
Study 33827960 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline plasma neurofilament light chain (NfL) concentrations measured with single-molecule array
Number of subjects: 574
Study 33827960 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma NfL
Number of subjects: 574